One of Recursion Pharmaceuticals’ internally developed drugs is advancing to late-stage clinical trials.
While only aiming at a relatively small opportunity, Wednesday’s announcement affirms the value of Recursion’s AI-powered pre-clinical-testing solution.
Just recognize that today’s seemingly volatile action isn’t unusual, and may largely be fueled by the stock’s recent extreme weakness.
Shares of pharmaceutical-development platform developer Recursion Pharmaceuticals (NASDAQ:RXRX) are soaring today in response to regulatory progress from one of its own drugs. Specifically, as of 11:59 a.m. ET this drug-design-technology name's stock is up by 5.4% following this morning's announcement that the U.S. Food and Drug Administration is in agreement with the company's design for Phase 3 trials of its REC-4881 -- an oral MEK1/2 inhibitor that treats familial adenomatous polyposis, or FAP.
While the FAP market is underserved, this step forward means more for the company than just developmental progress of one drug for the treatment of one illness. Just don't lose perspective on the matter.
Missed AI’s "Act 1"? Act 2 Could Be 15x Bigger. Most investors think they missed the AI boat because they didn't buy Nvidia in 2005. But according to our analysts, we’re only at the end of "Act 1"—the R&D phase. "Act 2" is the global rollout. Continue »
It's often categorized as a drug company, but that description doesn't quite do Recursion Pharmaceuticals justice. The company has developed an artificial intelligence platform capable of virtually pre-testing a potential drug molecule before time and money are spent on an actual clinical trial.
Image source: Getty Images.
A handful of major pharmaceutical outfits including Sanofi and Roche are partnering with Recursion in exchange for access to this platform too, but REC-4881 is one of Recursion Pharmaceuticals' own drugs. It's also now easily the one furthest along the developmental pipeline, with Phase 3 testing expected to begin in the latter half of next year.
While FAP is relatively rare, today's announcement reminds investors that Recursion's virtualized drug-development platform can lay the groundwork for the eventual creation of a very real drug. That's a big part of what's driving RXRX higher on Wednesday.
Just don't read too much into the bullish move. This ticker was already ripe for a sizable bounce, by virtue of tumbling more than 40% between its late-October peak and yesterday's new 52-week low. Also know that while today's news is clearly positive and the stock's gain is compelling, such single-day gains (or losses) aren't unusual for this volatile ticker.
The FDA's nod comes as no significant surprise either. Even if it required regulatory modifications, REC-4881's Phase 3 trial was bound to materialize at some point in the foreseeable future.
There's speculative potential upside here to be sure. Wednesday's announcement and move, though, don't actually bolster the bullish argument a great deal.
Before you buy stock in Recursion Pharmaceuticals, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Recursion Pharmaceuticals wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $321,850!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $955,232!*
Now, it’s worth noting Stock Advisor’s total average return is 793% — a market-crushing outperformance compared to 203% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
See the 10 stocks »
*Stock Advisor returns as of November 18, 2026.
James Brumley has no position in any of the stocks mentioned. The Motley Fool recommends Roche Holding AG. The Motley Fool has a disclosure policy.